skip to the content

Clinical Trials

Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)

Protocol ID

C11-318

Protocol Description

Transient Myeloproliferative Disorder (TMD) is found in young babies (less than 3 months old) with Down Syndrome and is caused by abnormal blood cells that travel throughout the body. TMD in children with Down Syndrome is not well understood. More information about TMD would help doctors to determine the best treatment for TMD in the future. The purpose of this study is to collect blood samples from TMD patients for medical research. Research doctors would like to learn more about the biology and characteristics of the disease. They will use samples collected on this study to understand why some of the cases of TMD develop into leukemia and why some don’t. They also want to understand what makes the TMD cells different from normal body cells and the types of liver changes that occur. Studies of the biology of TMD will help us learn more about TMD so that we can work towards finding a cure for this disease in the future.
 

Eligibility Criteria

• Patient is < 90 days of age at diagnosis of TMD
• Study enrollment must take place within 21 days following the diagnosis of TMD

Primary Investigator(s)

  • Arlene Redner, MD

Contact Information

Christine Grabowski
718-470-3401
cgrabows@nshs.edu

Ellen Bozza
718-470-3483
ebozza@nshs.edu

Last Update

November 16, 2011
top
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Children's Health:
top
top